IIM
RPRX icon

Ironwood Investment Management’s Royalty Pharma RPRX Stock Holding History

Ironwood Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,000
Closed -$405K – 171
2025
Q1 		$405K Hold
13,000
– – 0.22% 111
2024
Q4 		$332K Hold
13,000
– – 0.17% 131
2024
Q3 		$368K Hold
13,000
– – 0.18% 121
2024
Q2 		$343K Hold
13,000
– – 0.18% 119
2024
Q1 		$395K Buy
+13,000
New +$383K 0.19% 116

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $3.44B AUM 20.03% 1-Year Est. Return

Ironwood Investment Management's RPRX Position: Q2 2025 in Review

Ironwood Investment Management sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 13,000 shares — an estimated $405K sold.

Ironwood Investment Management first reported a position in RPRX in Q1 2024 and held it in 5 quarters. The position peaked at $405K in Q1 2025. 455 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

  • Ironwood Investment Management reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
  • Ironwood Investment Management sold 13,000 Royalty Pharma shares in Q2 2025, an estimated $405K.
  • Ironwood Investment Management first reported a position in Royalty Pharma in Q1 2024 and held it in 5 quarters.
  • Ironwood Investment Management's Royalty Pharma position peaked at $405K in Q1 2025.
  • 455 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Ironwood Investment Management's 13F filing for Q2 2025, filed 13 Aug 2025.